- World Pharma News Home » Clinical Trials » TRANSCEND® trial confirms long-term protective benefits and excellent tolerability profile
(a free service delivered by FeedBurner)
The results of the TRANSCEND® trial demonstrate that Micardis® 80mg (telmisartan) reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving best standard of care (p=0.048), referring to the same endpoint as that defined as the primary endpoint of the landmark HOPE trial published in 2000.[1,2] Therapy with telmisartan was well tolerated and showed a trend towards a lower rate of discontinuation.[1]
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments